Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

This study is testing roginolisib (IOA-244) combined with venetoclax and rituximab for patients with chronic lymphocytic leukemia (CLL) — a slow-growing blood cancer — that has come back or stopped responding to prior treatments including a BTK inhibitor. **You may be eligible if...** - You have been diagnosed with CLL that has relapsed or is no longer responding to treatment - You have received at least two prior CLL therapies, including a BTK inhibitor (such as ibrutinib or acalabrutinib) - You are 18 years or older - You are willing to have bone marrow biopsies before and during treatment - Your organ function (kidney, liver, blood counts) meets required levels **You may NOT be eligible if...** - You have active, symptomatic CLL that has spread to the central nervous system and is untreated - Your kidney function or blood counts fall significantly below required levels - You are pregnant or breastfeeding - You have other active cancers requiring treatment Talk to your doctor to see if this trial is right for you.